Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;267(3):830-837.
doi: 10.1007/s00415-019-09641-1. Epub 2019 Nov 27.

Classic ataxia-telangiectasia: the phenotype of long-term survivors

Nienke J H van Os  1   2 , Marcel van Deuren  3 , Corry M R Weemaes  4 , Judith van Gaalen  5 , Helma Hijdra  6 , Alexander M R Taylor  7 , Bart P C van de Warrenburg  5 , Michèl A A P Willemsen  8
Affiliations

Classic ataxia-telangiectasia: the phenotype of long-term survivors

Nienke J H van Os et al. J Neurol. 2020 Mar.

Abstract

Objective: Patients with classic ataxia-telangiectasia (A-T) generally die in the second or third decade of life. Clinical descriptions of A-T tend to focus on the symptoms at presentation. However, during the course of the disease, other symptoms and complications emerge. As long-term survivors with classic A-T develop a complex multisystem disorder with a largely unknown extent and severity, we aimed to comprehensively assess their full clinical picture.

Methods: Data from Dutch patients with classic A-T above the age of 30 years were retrospectively collected. In addition, we searched the literature for descriptions of classic A-T patients who survived beyond the age of 30 years.

Results: In the Dutch cohort, seven classic A-T patients survived beyond 30 years of age. Fourteen additional patients were retrieved by the literature search. Common problems in older patients with classic A-T were linked to ageing. Most patients had pulmonary, endocrine, cardiovascular, and gastro-intestinal problems. All patients had a tetraparesis with contractures. This led to immobilization and frequent hospital admissions. Most patients expressed the wish to no longer undergo intensive medical treatments, and waived follow-up programs.

Conclusions: Paucity of descriptions in the literature, and withdrawal from medical care complicate the acquisition of follow-up data on the natural history of long-term survivors. Irrespective of these limitations, we have obtained impression of the many problems that these patients face when surviving beyond 30 years of age. Awareness of these problems is needed to guide follow-up, counselling, and (palliative) care; decisions about life-prolonging treatments should be well considered.

Keywords: ATM gene; Ataxia–telangiectasia; Long-survivors; Louis–Bar syndrome; Prognosis.

PubMed Disclaimer

Conflict of interest statement

This study was funded by the Twan Foundation, Veenendaal, The Netherlands. Bart van de Warrenburg receives research support from ZonMW, Hersenstichting, Radboud university medical center, and Bioblast Pharma. The authors declare that they have no conflict of interest.

References

    1. Savitsky K, Bar-Shira A, Gilad S, Rotman G, Ziv Y, Vanagaite L, Tagle DA, Smith S, Uziel T, Sfez S, Ashkenazi M, Pecker I, Frydman M, Harnik R, Patanjali SR, Simmons A, Clines GA, Sartiel A, Gatti RA, Chessa L, Sanal O, Lavin MF, Jaspers NG, Taylor AM, Arlett CF, Miki T, Weissman SM, Lovett M, Collins FS, Shiloh Y. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. Science (New York, NY) 1995;268:1749–1753. doi: 10.1126/science.7792600. - DOI - PubMed
    1. Boder E. Ataxia-telangiectasia: an overview. Kroc Found series. 1985;19:1–63. - PubMed
    1. Lavin MF. Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol. 2008;9:759–769. doi: 10.1038/nrm2514. - DOI - PubMed
    1. van Os NJH, Jansen AFM, van Deuren M, Haraldsson A, van Driel NTM, Etzioni A, van der Flier M, Haaxma CA, Morio T, Rawat A, Schoenaker MHD, Soresina A, Taylor AMR, van de Warrenburg BPC, Weemaes CMR, Roeleveld N, Willemsen M. Ataxia-telangiectasia: immunodeficiency and survival. Clin Immunol (Orlando, Fla) 2017;178:45–55. doi: 10.1016/j.clim.2017.01.009. - DOI - PubMed
    1. Crawford TO, Skolasky RL, Fernandez R, Rosquist KJ, Lederman HM. Survival probability in ataxia telangiectasia. Arch Dis Child. 2006;91:610–611. doi: 10.1136/adc.2006.094268. - DOI - PMC - PubMed